One-Year Functional and Morphological Prognosis After Intravitreal Injection Treatments According to Different Morphological Patterns of Diabetic Macular Edema in Real-Life: MARMASIA Study Group Report No.13

References

• Mansour SE, Browning DJ, Wong K, et al. The evolving treatment of diabetic retinopathy.Clin Ophthalmol. 2020;14:653–678. doi:10.2147/OPTH.S236637.
   Google Scholar
• Bandello F, Cicinelli MV. 19th EURETINA congress keynote lecture: diabetic retinopathy Today. Ophthalmologica 2020 19th;243(3):163–171. doi:10.1159/000506312.
   Web of Science ®Google Scholar
• Tan GS, Cheung N, Simo R, et al. Diabetic macular edema. Lancet Diabetes Endocrinol. 2017;5(2):143–155. doi:10.1016/S2213-8587(16)30052-3.
   PubMed Web of Science ®Google Scholar
• James DGP, Mitkute D, Porter G, et al. Visual outcomes following intravitreal ranibizumab for diabetic macular edema in a pro re nata protocol from baseline: a real-world experience.Asia Pac. J Ophthalmol (Phila). 2019;8:200–205.
   Web of Science ®Google Scholar
• Ashraf M, Souka A, Adelman R. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular edema: a review of the literature. Br J Ophthalmol. 2016;100(12):1596–1604. doi:10.1136/bjophthalmol-2016-308388.
   Web of Science ®Google Scholar
• Bressler NM, Beaulieu WT, Glassman AR, et al. Persistent macular thickening following intravitreous aflibercept, Bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial JAMA ophthalmol. JAMA Ophthalmol. 2018;136(3):257–269. doi:10.1001/jamaophthalmol.2017.6565.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–1359. doi:10.1016/j.ophtha.2016.02.022.
   PubMed Web of Science ®Google Scholar
• Maturi RK, Glassman AR, Liu D, et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmol. 2018;136(1):29–38. doi:10.1001/jamaophthalmol.2017.4914.
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report number 1. Arch Ophthalmol. 1985;103(12):1796–1806. doi:10.1001/archopht.1985.01050120030015.
   PubMed Web of Science ®Google Scholar
• Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology. 2018;125(10):1608–1622. doi:10.1016/j.ophtha.2018.04.007.
   PubMed Web of Science ®Google Scholar
• Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol. 1999;127(6):688–693. doi:10.1016/S0002-9394(99)00033-1.
   PubMed Web of Science ®Google Scholar
• Arf S, Muslubas I, Hocaoglu M, et al. Spectral-domain optical coherence tomography classification of diabetic macular edema: a new proposal to clinical practice.Graefes Arch Clin Exp Ophthalmol. 2020;258(6):1165–1172. doi:10.1007/s00417-020-04640-9.
   Google Scholar
• Panozzo G, Cicinelli M, Augustin A, et al. An optical coherence tomography-based grading of diabetic maculopathy proposed by an international expert panel: the European school for advanced studies in. Ophthalm Classifica Eur J Ophthalmol. 2020;30(1):8–18. doi:10.1177/1120672119880394.
   Web of Science ®Google Scholar
• Yayla U, Sevik M, Karabaş V, et al. Real-world outcomes of Intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema in Türkiye: MARMASIA study group report No. 1. Turk J Ophthalmol Ahead Of Print. 10 August 2023;53(6):356–368. doi:10.4274/tjo.galenos.2023.56249.
   Google Scholar
• Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European society of retina specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222. doi:10.1159/000458539.
   PubMed Web of Science ®Google Scholar
• Bringmann A, Reichenbach A, Wiedemann P. Pathomechanisms of cystoid macular edema. Ophthalmic Res. 2004;36(5):241–249. doi:10.1159/000081203.
   PubMed Web of Science ®Google Scholar
• Yanoff M, Fine BS, Brucker AJ, et al. Pathology of human cystoid macular edema. Surv Ophthalmol. 1984;28:505–511. doi:10.1016/0039-6257(84)90233-9.
   PubMed Web of Science ®Google Scholar
• Xu M, Xu H, Li X, et al. Characteristics of macular morphology and microcirculation in diabetic macular edema patients with serous retinal detachment. BMC Ophthalmol. 2022;22(1):299. doi:10.1186/s12886-022-02523-7.
   Web of Science ®Google Scholar
• Kim BY, Smith SD, Kaiser PK. Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol. 2006;142(3):405–412.e1. doi:10.1016/j.ajo.2006.04.023.
   PubMed Web of Science ®Google Scholar
• Roh MI, Kim JH, Kwon OW. Features of optical coherence tomography are predictive of visual outcomes after intravitreal bevacizumab injection for diabetic macular edema. Ophthalmologica. 2010;224(6):374–380. doi:10.1159/000313820.
   Web of Science ®Google Scholar
• Wu PC, Lai CH, Chen CL, et al. Optical coherence tomographic patterns in diabetic macular edema can predict the effects of intravitreal bevacizumab injection as primary treatment. J Ocul Pharmacol Ther. 2012;28(1):59–64. doi:10.1089/jop.2011.0070.
   Web of Science ®Google Scholar
• Shimura M, Yasuda K, Nakazawa T, et al. Visual outcome after intravitreal triamcinolone acetonide depends on optical coherence tomographic patterns in patients with diffuse diabetic macular edema. Retina. 2011;31(4):748–754. doi:10.1097/IAE.0b013e3181f04991.
   PubMed Web of Science ®Google Scholar
• Ozcaliskan S, Balci S, Karasu B, Artunay O. Effect of optical coherence tomography patterns on one-year outcomes of aflibercept therapy for diabetic macular edema. J Coll Physicians Surg Pak. 2020;30(2):149–153. doi:10.29271/jcpsp.2020.02.149.
   Web of Science ®Google Scholar
• Ercalik NY, Imamoglu S, Turkseven Kumral E, et al. Influence of serous retinal detachment on the outcome of ranibizumab treatment in diabetic macular oedema. Cutan Ocul Toxicol. 2018;37(4):324–327. doi:10.1080/15569527.2018.1459667.
   PubMed Web of Science ®Google Scholar
• Koytak A, Altinisik M, Sogutlu Sari E, et al. Effect of a single intravitreal bevacizumab injection on different optical coherence tomographic patterns of diabetic macular edema. Eye. 2013;27(6):716–721. doi:10.1038/eye.2013.17.
   Web of Science ®Google Scholar
• Ozsaygili C, Duru N. Comparison of intravitreal dexamethasone implant and aflibercept in patients with treatment-naive diabetic macular edema with serous retinal detachment. Retina. 2020;40(6):1044–1052. doi:10.1097/IAE.0000000000002537.
   PubMed Web of Science ®Google Scholar
• Kim M, Lee P, Kim Y, et al. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema. Ophthalmologica. 2011;226(3):138–144. doi:10.1159/000330045.
   Web of Science ®Google Scholar